A5015776541- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Paraoxonase enzyme and polymorphisms
- Cynara cardunculus studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Galectins and Cancer Biology
- Thyroid Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Cytomegalovirus and herpesvirus research
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Adenosine and Purinergic Signaling
- RNA modifications and cancer
- Helicobacter pylori-related gastroenterology studies
- Liver Disease and Transplantation
- Diabetes Treatment and Management
- Cancer, Hypoxia, and Metabolism
- Dialysis and Renal Disease Management
Ain Shams University
2008-2025
Treatment of chronic hepatitis C using combination sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials multicentre studies, which were somewhat limited to genotypes 1-3. The national program Egypt is SOF-DCV for large scale treatment.To assess the efficacy safety combined treating patients with HCV-G4 a real-world setting.Data outcome HCV who treated 12 weeks generic medications: DCV 60 mg plus SOF 400 ± ribavirin (RBV) within treatment are presented. Treatment-naïve...
<title>Abstract</title> <bold>Background: </bold>Hepatocellular carcinoma (HCC) is the sixth prevailing cancer globally and second greatest reason for cancer-linked deaths in males, surpassed only by lung cancer. A significant number of HCC cases experiencing advanced stages are due to frequent absence or inconspicuousness early symptoms. Consequently, discovering reliable diagnostic indicators innovative treatment targets essential improve survival overall outcomes patients. Herein, we...
Abstract Background Hepatocellular carcinoma (HCC) is the sixth prevailing cancer globally and second greatest reason for cancer-linked deaths in males, surpassed only by lung cancer. A significant number of HCC cases experiencing advanced stages are due to frequent absence or inconspicuousness early symptoms. Consequently, discovering reliable diagnostic indicators innovative treatment targets essential improve survival overall outcomes patients. Herein, we aimed evaluate potential APEX1...
A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This depended mainly on establishing specialized independent centres treatment. These represent major strengths in model care, as they provide integrated care patients and have enabled Egypt to treat more than one million 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example these centres.The experience management evaluated by analysing data...
Paraoxonase is a high-density lipoprotein-associated enzyme and has been shown to reduce the susceptibility low-density lipoprotein peroxidation. This study aimed investigate activity of serum paraoxonase in uremic patients on hemodialysis (HD) predialysis period, evaluate correlations vascular disease with activity. Thirty chronic renal failure (CRF) undergoing HD (group 1), 30 CRF under conservative treatment 2), healthy controls 3) were included. Basal, salt-stimulated, arylesterase...
Treatment of hepatitis C virus (HCV) genotype 4 patient with fixed dose combination ombitasvir-paritaprevir-ritonavir plus ribavirin (OBV/rPTV/RBV) has been proven efficacy and safety in many clinical trials. The current study reports the OBV/rPTV/RBV (for treatment-naïve), OBV/rPTV/RBV/sofosbuvir (SOF) treatment-experienced), chronic HCV patients real life settings.Prospective cohort including all adult who were scheduled to receive ± SOF for 12 or 24 weeks New Cairo Viral Hepatitis Center....
The aim of this study was to retrospectively analyze the outcome an unscheduled change in national Egyptian policies for treatment hepatitis C virus (HCV), which transpired as a result reduction interferon supplies, and manage patients who already started interferon-based therapy. After completing priming 4-weeks course sofosbuvir/pegylated interferon/ribavirin (SOF/PEG IFN/RBV), 12-weeks sofosbuvir/daclatasvir (SOF/DCV) combination initiated. We evaluated sustained virologic response at 12...
Aim: Evaluation of the efficacy and safety sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV) in treating non-sustained virological responders (non-SVR12) to prior sofosbuvir-based therapy, absence RAS testing mass treatment, determination optimal timing start re-treatment. Methods: Real-life prospective observational study included non-responders 24-weeks SOF-RBV (n = 679, 67%) or 12-weeks SOF- RBV- PEG 335, 33%). Patients were re-treated with daily SOF/DCV/RBV for 12 270) 24 weeks 744). The...
Abstract Objectives The main objective of this research was to study evaluate the diagnostic accuracy serum chitinase-3 like protein-1 (CHI3L1) in comparison with transient elastography (TE) and non- invasive indirect indices (Fib-4 APRI) for prediction significant hepatic fibrosis patients chronic HBV infection. Methods current cross-sectional carried out on 30 individuals CHB who attended viral hepatitis unit outpatient clinic, Faculty Medicine, Ain Shams University, from Aug-2021...
Abstract Background Cure of chronic hepatitis C (HCV) in HIV/HCV co-infected patients is a priority due to their increased risk complications. Daclatasvir and sofosbuvir treatment regimens with or without ribavirin are considered an important chance for better HCV co-infection. This study aimed at the assessment safety efficacy sofosbuvir-daclatasvir Egyptian patients. Results Thirty adult were included. All completed duration major problems drug interactions, PCR was negative all end...
<ns7:p><ns7:bold>Background:</ns7:bold> Treatment of chronic hepatitis C (CHC) with direct acting antivirals (DAAS) improves the rates sustained virological response (SVR). However, derangements lipid profile and glycemic status have been observed. This study aimed to compare effect sofosbuvir/daclatasvir (SOF/DAC) versus sofosbuvir/ledipasvir (SOF/LED) regimens on metabolic CHC patients.</ns7:p><ns7:p> <ns7:bold>Methods: </ns7:bold>An observational prospective was conducted a total 140...
Abstract Background The introduction of direct-acting antiviral agents, has revolutionized the treatment for chronic HCV with higher cure rates, shorter duration and more tolerability have been achieved. Objectives aim our study is to estimate efficacy safety DAAs in patients co-infected HIV. Patients Methods This previously untreated HIV co- infection conducted at Abbasia Fever Hospital, from July 2019 February 2020. included those who are receiving antiretroviral therapy a CD4 T-lymphocyte...